Literature DB >> 12660662

Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results?

Daisy G M Bloemenkamp1, Willem P Th M Mali, Frank L J Visseren, Yolanda van der Graaf.   

Abstract

BACKGROUND: The results of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherogenesis vary considerably. A meta-analysis was performed to calculate the overall odds ratio (OR) and to identify potential sources of variability.
METHODS: The MEDLINE database was searched from January 1997 to December 2000 for studies describing the seroprevalence of IgG antibodies to C pneumoniae in relation to clinically manifest atherosclerosis. Data extracted included 1) the study design used, 2) the number of included patients, 3) the type of disease (or end point), 4) the number of control subjects, 5) the type of control subjects, 6) the follow-up duration, 7) the crude and adjusted ORs (and 95% CI), and 8) the extent of adjustment for potential confounders.
RESULTS: Thirty-eight studies were included in the meta-analysis. The overall OR was 1.6 (95% CI 1.3-2.0). The overall OR of cross-sectional case-control studies (2.0, 95% CI 1.5-2.6) was higher than that of prospective (nested) case-control studies (1.1, 95% CI 0.8-1.4). Moreover, the duration of follow-up in prospective studies was inversely related to the strength of the relation (beta = -0.04, 95% CI -0.08, -0.01). Adjustment of risk estimates for potentially confounding factors did not influence the strength of the relation.
CONCLUSIONS: The relation between C pneumoniae and clinically manifest atherosclerosis is not durable. This probably is due to a lack of causality, although results may have been influenced by the design of the component studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660662     DOI: 10.1067/mhj.2003.20

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Impact of serological methodology on assessment of the link between Chlamydia pneumoniae and vascular diseases.

Authors:  Boulos Maraha; Martin den Heijer; Jan Kluytmans; Marcel Peeters
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Chlamydial bacteriophage: No role in acute coronary events?

Authors:  David M Patrick; Karuna Karunakaran; Adrian R Levy; Kenneth Gin; Valencia Remple; Mei Chong; Heather Abbey; Laura Tarry; Caixia Shen; Robert C Brunham
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-09       Impact factor: 2.471

3.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

4.  Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial.

Authors:  Hans F Berg; Boulos Maraha; Anneke van der Zee; Siska K Gielis; Paul J M Roholl; Gert-Jan Scheffer; Marcel F Peeters; Jan A J W Kluytmans
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Antibiotics for secondary prevention of coronary heart disease.

Authors:  Naqash J Sethi; Sanam Safi; Steven Kwasi Korang; Asbjørn Hróbjartsson; Maria Skoog; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-02-23

6.  Chlamydophila pneumoniae infection and cardiovascular disease.

Authors:  Rajnish Joshi; Bidita Khandelwal; Deepti Joshi; Om Prakash Gupta
Journal:  N Am J Med Sci       Date:  2013-03

Review 7.  Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials.

Authors:  Catherine Liu; David D Waters
Journal:  Prog Cardiovasc Dis       Date:  2005 Jan-Feb       Impact factor: 8.194

Review 8.  Chlamydia pneumoniae infection and cerebrovascular disease: a systematic review and meta-analysis.

Authors:  Juan Chen; Meijia Zhu; Gaoting Ma; Zhangning Zhao; Zhongwen Sun
Journal:  BMC Neurol       Date:  2013-11-21       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.